RET and lung carcinoma: Taking BLU-667 as an example, it was reported to have 88-fold more potency against RET than VEGFR [34], and it has already demonstrated clinical benefits in RET-altered thyroid cancer and lung cancer patients in early stage clinical trials [35, 36] .